drugset
drugset / Trial / NCT00939653

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

NCT00939653 ↗

Phase 2 Terminated 6 enrolled Therapeutic Advances in Childhood Leukemia Consortium Genzyme, a Sanofi Company · collab
NaSingle-groupOpen-labelTreatment

Summary

Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs. Clofarabine will be used together with etoposide (VePesid®, VP-16) and cyclophosphamide (Cytoxan®).

Timeline

Start
2009-07-10
Primary completion
2011-07-15
Completion
2011-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Clofarabine Other / unclassified 40 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 440 mg/m2 Intravenous
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Background Cytarabine Small molecule 30 mg Intrathecal
Background Cytarabine Small molecule 50 mg Intrathecal
Background Cytarabine Small molecule 70 mg Intrathecal
Background filgrastim Protein / enzyme biologic 5 ug/kg Intravenous

Indications

acute myeloid leukemia